Loading...
Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?
Compelling evidence indicates Type I CD20 immunotherapeutic mAbs promote targeted tumor cell elimination exclusively via immune effector functions, which can be exhausted/saturated. mAb dosing paradigms should therefore take into account the capacity of these cytotoxic mechanisms, leading to the con...
Na minha lista:
| Main Authors: | , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Landes Bioscience
2012
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3489759/ https://ncbi.nlm.nih.gov/pubmed/23162771 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/onci.20368 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|